Recent progress in molecular mechanisms of angiotensin II type 1 and 2 receptors

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 2981-2987

  Miura, Shin ichiro ^a,b   Imaizumi, Satoshi ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin II receptors; G protein coupled receptor; Structure and function

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; OPSIN; RHODOPSIN;

CRYSTAL STRUCTURE; DIMERIZATION; HEART HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION; VASOCONSTRICTION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 84878647353     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170002     Document Type: Review

References (100)

1. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
2. Hiroi Y, Hiroi J, Kudoh S, Yazaki Y, Nagai R, Komuro I. Two distinct mechanisms of angiotensin II-induced negative regulation of the mitogen-activated protein kinases in cultured cardiac myocytes. Hypertens Res 2001; 24: 385-94.
3. Horiuchi M, Hamai M, Cui TX, Iwai M, Minokoshi Y. Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Hypertens Res 1999; 22: 67-74.
4. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21: 90-113.
5. Peleg G, Ghanouni P, Kobilka BK, Zare RN. Single-molecule spectroscopy of the beta(2) adrenergic receptor: observation of conformational substates in a membrane protein. Proc Natl Acad Sci USA 2001; 98: 8469-74.
6. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-45.
7. Scheerer P, Park JH, Hildebrand PW, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008; 455: 497-502.
8. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008; 454: 183-7.
9. Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-65.
10. Rosenbaum DM, Cherezov V, Hanson MA, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007; 318: 1266-73.
11. Rosenbaum DM, Zhang C, Lyons JA, et al. Structure and function of an irreversible agonist-(2) adrenoceptor complex. Nature 2011; 469: 236-40.
12. Rasmussen SG, Choi HJ, Fung JJ, et al. Structure of a nanobodystabilized active state of the (2) adrenoceptor. Nature 2011; 469: 175-80.
13. Warne T, Moukhametzianov R, Baker JG, et al. The structural basis for agonist and partial agonist action on a (1)-adrenergic receptor. Nature 2011; 469: 241-4.
14. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001; 40: 7761-72.
15. Menon ST, Han M, Sakmar TP. Rhodopsin: structural basis of molecular physiology. Physiol Rev 2001; 81: 1659-88.
16. Inoue Y, Nakamura N, Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 1997; 15: 703-14.
17. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 2011; 121: 297-303.
18. Yamano Y, Ohyama K, Chaki S, Guo DF, Inagami T. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site-directed mutagenesis. Biochem Biophys Res Commun 1992; 187: 1426-31.
19. Noda K, Saad Y, Kinoshita A, et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270: 2284-89.
20. Feng YH, Noda K, Saad Y, Liu XP, Husain A, Karnik SS. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem 1995; 270: 12846-50.
21. Le MT, Vanderheyden PM, Szaszák M, Hunyady L, Vauquelin G. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem 2002; 277: 23107-10.
22. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14: 303-7.
23. Noda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 1996; 35: 16435-42.
24. Noda K, Saad Y, Karnik SS. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem 1995; 270: 28511-4.
25. Monnot C, Bihoreau C, Conchon S, Curnow KM, Corvol P, Clauser E. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem 1996; 271: 1507-13.
26. Groblewski T, Maigret B, Larguier R, Lombard C, Bonnafous JC, Marie J. Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J Biol Chem 1997; 272: 1822-6.
27. Feng YH, Miura S, Husain A, Karnik SS. Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry 1998; 37: 15791-8.
28. Miura S, Feng YH, Husain A, Karnik SS. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 1999; 274: 7103-10.
29. Holloway AC, Qian H, Pipolo L, et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 2002; 61: 768-77.
30. Clément M, Martin SS, Beaulieu ME, et al. Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay. J Biol Chem 2005; 280: 27121-9.
31. Groblewski T, Maigret B, Nouet S, et al. Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands. Biochem Biophys Res Commun 1995; 209: 153-60.
32. Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW. Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 1994; 269: 30953-9.
33. Costa-Neto CM, Miyakawa AA, Oliveira L, Hjorth SA, Schwartz TW, Paiva ACM. Mutational analysis of the interaction of N-and C-terminal ends of angiotensin II with the AT1 receptor. Br J Pharmacol 2000; 130: 1263-8.
34. Pérodin J, Deraët M, Auger-Messier M, et al. Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor. Biochemistry 2002; 41: 14348-56.
35. Miura S, Karnik SS. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens 1999; 17: 397-404.
36. Capponi AM, Catt KJ. Angiotensin II receptors in adrenal cortex and uterus. Binding and activation properties of angiotensin analogues. J Biol Chem 1979; 254: 5120-7.
37. Marie J, Koch C, Pruneau D, et al. Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 1999; 55: 92-101.
38. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 1996; 49: 112-22.
39. Zuscik MJ, Porter JE, Gaivin R, Perez DM. Identification of a conserved switch residue responsible for selective constitutive activation of the beta2-adrenergic receptor. J Biol Chem 1998; 273: 3401-7.
40. Zhang Q, He F, Kuruba R, et al. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc Res 2008; 77: 560-9.
41. Servant G, Laporte SA, Leduc R, Escher E, Guillemette G. Identification of angiotensin II-binding domains in the rat AT2 receptor with photolabile angiotensin analogs. J Biol Chem 1997; 272: 8653-9.
42. Miura S, Zhang B, Karnik SS. Angiotensin II type 1 receptorfunction affected by mutations in cytoplasmic loop CD. FEBS Lett 2000; 470: 331-5.
43. Shibata T, Suzuki C, Ohnishi J, Murakami K, Miyazaki H. Identification of regions in the human angiotensin II receptor type 1 responsible for Gi and Gq coupling by mutagenesis study. Biochem Biophys Res Commun 1996; 218: 383-9.
44. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 2002; 277: 9268-77.
45. Gáborik Z, Jagadeesh G, Zhang M, Spat A, Catt KJ, Hunyady L. The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology 2003; 144: 2220-8.
46. Hansen JL, Theilade J, Haunsø S, Sheikh SP. Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits G q protein signaling but not ERK activation. J Biol Chem 2004; 279: 24108-15.
47. Conchon S, Barrault MB, Miserey S, Corvol P, Clauser E. The Cterminal third intracellular loop of the rat AT1A angiotensin receptor plays a key role in G protein coupling specificity and transduction of the mitogenic signal. J Biol Chem 1997; 272: 25566-72.
48. Olivares-Reyes JA, Smith RD, Hunyady L, Shah BH, Catt KJ. Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT1A angiotensin receptor. J Biol Chem 2001; 276: 37761-8.
49. Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res 2002; 25: 641-6.
50. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-69.
51. Unal H, Jagannathan R, Bhat MB, Karnik SS. gand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 2010; 285: 16341-50.
52. Gurevich VV, Gurevich EV. The structural basis of arrestinmediated regulation of G-protein-coupled receptors. Pharmacol Ther 2006; 110: 465-502.
53. Qian H, Pipolo L, Thomas WG. Association of beta-arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization. Mol Endocrinol 2001; 15: 1706-19.
54. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000; 275: 17201-10.
55. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. Agonistinduced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA 2001; 98: 5997-6002.
56. Miura S, Karnik SS. Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane Helix-2. J Biol Chem 2002; 277: 24299-305.
57. Miura S, Zhang J, Boros J, Karnik SS. TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor. J Biol Chem 2003; 278: 3720-5.
58. Domazet I, Holleran BJ, Martin SS, et al. The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation. J Biol Chem 2009; 284: 11922-9.
59. Boucard AA, Roy M, Beaulieu ME, et al. Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket. J Biol Chem 2003; 278: 36628-36.
60. Martin SS, Boucard AA, Clément M, Escher E, Leduc R, Guillemette G. Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis. J Biol Chem 2004; 279: 51415-23.
61. Martin SS, Holleran BJ, Escher E, Guillemette G, Leduc R. Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method. Mol Pharmacol 2007; 72: 182-90.
62. Domazet I, Martin SS, Holleran BJ, et al. The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation. J Biol Chem 2009; 284: 31953-61.
63. Yan L, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R. Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis. J Biol Chem 2010; 285: 2284-93.
64. Feng YH, Karnik SS. Role of transmembrane helix IV in G-protein specificity of the angiotensin II type 1 receptor. J Biol Chem 1999; 274: 35546-52.
65. Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ, Luttrell LM.-arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 2002; 277: 9429-36.
66. Wei H, Ahn S, Shenoy SK, et al. Independet beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci 2003; 100: 10782-7.
67. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 2004; 279: 35518-25.
68. Miura S, Saku K, Karnik SS. Selective signal transduction through AT1 receptor induced by angiotensin II. Circ J 2002; 66: 636 (Abstract).
69. Lyngso C, Erikstrup N & Hansen JL. Functional interactions between 7TM receptors in the Renin-Angiotensin System-Dimerization or crosstalk? Mol Cell Endocrinol 2009; 302: 203-12.
70. Smith NJ, Chan HW, Osborne JE, Thomas WG, Hannan RD. Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci 2004; 61: 2695-703.
71. Mifune M, Ohtsu H, Suzuki H, et al. G protein coupling and second messenger generation are indispensable for metalloproteasedependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 2005; 280:26592-9.
72. Aplin M, Christensen GL, Schneider M, et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and-independent pathways in cardiac myocytes and Langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 2007; 100: 289-295.
73. Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 2007; 100: 296-301.
74. Aplin M, Christensen GL, Hansen JL. Pharmacologic Perspectives of Functional Selectivity by the Angiotensin II Type 1 Receptor. Trends Cardiovasc Med 2008; 18: 305-12.
75. Bais C, Santomasso B, Coso O, et al. G-protein coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391: 86-9.
76. Seifert R, Wenzel-Seifert K. Constitutive activity of G-proteincoupled receptors: cause of disease and common property of wildtype receptors. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 381-416.
77. Costa T, Ogino Y, Munson PJ, Onaran HO, Rodbard D. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 1992; 41: 549-60.
78. Schutz W, Freissmuth M. Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol Sci 1992; 13: 376-80.
79. Miura S, Karnik SS. Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J 2000; 19: 4026-35.
80. Morisset S, Rouleau A, Ligneau X, et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000; 408: 860-4.
81. Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008;22:139-46.
82. Miura S, Ramchandran R, Chang CS, et al. Changes in cell cycle regulation during angiotensin II type 1 receptor-mediated cell growth. FASEB J 1999; 13: A1537 (Abstract).
83. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-7.
84. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
85. Yasuda N, Miura S, Akazawa H, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9: 179-86.
86. Yasuda N, Akazawa H, Ito K, et al. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension 2012; 59: 627-33.
87. Miura S, Karnik SS. Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J 2000; 19: 4026-35.
88. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700.
89. Hebert TE, Loisel TP, Adam L, Ethier N, Onge SS, Bouvier M. Functional rescue of a constitutively desensitized beta2AR through receptor dimerization. Biochem J 1998; 330: 287-93.
90. Maggio R, Barbier P, Fornai F, Corsini GU. Functional role of the third cytoplasmic loop in muscarinic receptor dimerization. J Biol Chem 1996; 271: 31055-60.
91. Ng GY, OiDowd BF, Lee SP, et al. Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 1996; 227: 200-4.
92. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000; 407: 94-8.
93. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003-9.
94. Szalai B, Barkai L, Turu G, Szidonya L, Várnai P, Hunyady L. Allosteric interactions within the AT(1) angiotensin receptor homodimer: Role of the conserved DRY motif. Biochem Pharmacol 2012. in press.
95. Yamada M, Kushibiki M, Osanai T, Tomita H, Okumura K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res 2008; 79: 169-78.
96. Quitterer U, Pohl A, Langer A, Koller S, Abdalla S. A cleavable signal peptide enhances cell surface delivery and heterodimerization of Cerulean-tagged angiotensin II AT1 and bradykinin B2 receptor. Biochem Biophys Res Commun 2011; 409: 544-9.
97. Miura S, Karnik SS, Saku K. Constitutively active homooligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem 2005; 280: 18237-44.
98. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276: 39721-6.
99. Miura S, Matsuo Y, Kiya Y, Karnik SS, Saku K. Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem Biophys Res Commun. 2010; 391: 85-90.
100. Ferrão FM, Lara LS, Axelband F, et al. Exposure of luminal membranes of LLC-PK1 cells to ANG II induces dimerization of AT1/AT2 receptors to activate SERCA and to promote Ca2+ mobilization. Am J Physiol Renal Physiol 2012; 302: F875-83.